> Research Disclaimer: BPC-157 is a synthetic research peptide not approved by the FDA for human therapeutic use. This article summarizes publicly available scientific literature for educational and research purposes only. Not for human use.
What Is BPC-157?
BPC-157 — short for Body Protective Compound 157 — is a synthetic pentadecapeptide comprising 15 amino acids. It was originally isolated and characterized from a naturally occurring protein found in human gastric juice, which researchers termed "body protective compound" (BPC) due to its cytoprotective properties in the gastrointestinal tract. The sequence of BPC-157 is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
Preclinical research over the past three decades has made BPC-157 one of the most extensively studied synthetic research peptides, with published studies examining its effects across gastrointestinal healing, tendon and ligament repair, bone healing, central nervous system function, and systemic anti-inflammatory activity. Its research interest stems from its apparent pleiotropic activity — the ability to modulate multiple biological systems through distinct but overlapping pathways.
Unlike many peptides derived from growth factor sequences, BPC-157 does not correspond to a known endogenous growth factor. Its sequence has no direct mammalian homolog, which makes it particularly interesting from a pharmacological standpoint: its biological activity appears to arise from its unique structural conformation rather than from mimicking a known signaling molecule.
---
Molecular Structure and Stability
BPC-157 has a molecular weight of approximately 1419.5 Da. Its amino acid sequence confers notable stability properties that distinguish it from many other research peptides:
- •Gastric stability: Unlike most peptides, BPC-157 resists proteolytic degradation in gastric acid conditions, which aligns with its origin in gastric juice protein. This stability has generated research interest in oral administration routes, not merely injectable formulations.
- •Injectable stability: Lyophilized (freeze-dried) BPC-157 is stable at room temperature for short periods but should be stored at -20°C for long-term integrity. Once reconstituted in bacteriostatic water, it should be kept refrigerated and typically used within 30 days.
- •pH stability: Research indicates BPC-157 maintains structural integrity across a broad pH range, consistent with its gastric juice origin.
In research settings, BPC-157 is studied in two primary forms:
| Form | Route | Notes |
|---|---|---|
| Injectable (lyophilized vial) | Subcutaneous, intramuscular, IP | Most studied; fast systemic distribution |
| Oral (capsule/solution) | Oral gavage | Emerging research interest; exploits gastric stability |
Early animal studies largely used injectable administration, but a growing body of research has explored oral BPC-157 for gut-targeted effects, reflecting the peptide's origin in the gastrointestinal system.
---
Mechanisms of Action
BPC-157's diverse research applications stem from several interrelated mechanisms, each supported by preclinical evidence:
1. Angiogenesis and VEGF Upregulation
One of the most consistently documented effects of BPC-157 in preclinical models is promotion of angiogenesis — the formation of new blood vessels. Research has shown that BPC-157 upregulates vascular endothelial growth factor (VEGF) expression and activates VEGF receptor signaling pathways. This angiogenic activity is believed to underlie much of its observed healing effects: new capillary formation accelerates delivery of oxygen, nutrients, and immune cells to damaged tissue.
In tendon research models, BPC-157 administration was associated with significantly increased capillary density at repair sites, correlating with faster histological healing scores.
2. Growth Factor Pathway Modulation
BPC-157 appears to interact with multiple growth factor signaling cascades beyond VEGF:
- •EGF (Epidermal Growth Factor): Research suggests BPC-157 may potentiate EGF receptor signaling, contributing to epithelial cell proliferation in gut tissue.
- •FGF-2 (Fibroblast Growth Factor-2): Studies in ligament healing models documented elevated FGF-2 expression following BPC-157 administration, consistent with the peptide's tendon repair activity.
- •TGF-β pathway: Some research suggests modulation of transforming growth factor-beta, which plays roles in fibrosis regulation and wound healing.
3. Nitric Oxide (NO) System Modulation
A major proposed mechanism for BPC-157's systemic effects involves the nitric oxide (NO) system. Research in animal models has demonstrated that BPC-157 influences both endothelial nitric oxide synthase (eNOS) and neuronal NOS (nNOS) activity. This NO modulation has implications for:
- •Vascular tone and blood pressure regulation
- •Cytoprotection in ischemia-reperfusion injury models
- •Neuroprotection in CNS injury models
A key published study (PMID ) examined BPC-157's interaction with the NO system and its role in mediating the compound's cytoprotective effects across multiple organ systems. The authors proposed that NO pathway engagement is central to BPC-157's observed breadth of activity.
4. Tendon-to-Bone Healing
BPC-157 has been extensively studied in tendon and ligament healing models, representing one of its most robust research applications. Studies in rat models of Achilles tendon transaction and ligament injuries demonstrated:
- •Accelerated collagen fibril organization
- •Increased tensile strength of healing tendons
- •Upregulation of tendon-specific markers (collagen type I, tenocyte markers)
A pivotal study (PMID ) demonstrated that BPC-157 significantly improved healing in transected Achilles tendons in rats, with treated animals showing superior functional recovery and histological repair quality compared to controls. The researchers identified increased VEGF expression and collagen deposition as key mediators.
5. Gut Mucosal Protection and Healing
BPC-157's origins in gastric juice protein are reflected in its potent gastrointestinal effects in preclinical models. Research has demonstrated:
- •Cytoprotection against NSAID-induced gastric ulcers
- •Acceleration of intestinal anastomosis healing
- •Protection against inflammatory bowel disease models (TNBS-induced colitis)
- •Preservation of intestinal barrier function under stress conditions
A foundational gut healing study (PMID ) examined BPC-157's effects on colonic mucosal healing in experimental colitis models, demonstrating significantly accelerated mucosal repair and reduced inflammatory infiltration in treated animals compared to controls.
---
Key Research Findings
The following table summarizes landmark preclinical studies on BPC-157:
| Study Focus | Model | Key Finding | PMID |
|---|---|---|---|
| CNS injury | Rat TBI model | Neuroprotection; improved functional recovery | Various |
| Bone healing | Rat fracture model | Accelerated callus formation; improved ossification | Various |
| Systemic anti-inflammatory | Multiple | Multi-organ cytoprotection | Various |
Important research caveat: The overwhelming majority of BPC-157 studies are conducted in rodent models. Human clinical trial data for BPC-157 is extremely limited, and preclinical findings do not automatically translate to human therapeutic applications.
---
Research Forms Available
BPC-157 is available in the research market in several forms, each with different characteristics:
Injectable (Lyophilized Vial)
The most common and most studied form. Requires reconstitution with bacteriostatic water before use in research. Standard research vials are available in 5mg quantities. This route has the most extensive preclinical literature support.
Oral Capsules
Emerging research has examined oral BPC-157 for gut-targeted applications, exploiting the peptide's gastric stability. Oral formulations are available from some suppliers, typically in capsule form.
Subcutaneous vs. Systemic Routes
Preclinical research has used subcutaneous (SC), intramuscular (IM), and intraperitoneal (IP) routes in animal models. SC is most commonly referenced in human-context research discussions.
---
Platform Pricing
For current BPC-157 research pricing across verified suppliers, compare live listings at peptides.so/compare/bpc-157 and the BPC-157 peptide page.
Based on current platform data, BPC-157 5mg injectable vials are priced in the range of $37–$65 from established research suppliers, representing a per-mg cost of approximately $0.24–$0.65. Pricing varies based on supplier reputation, COA documentation, and vial quantity.
Use the Peptides Calculator to estimate research quantities and costs.
---
Stacking Considerations in Research
BPC-157 is commonly studied alongside other research peptides:
BPC-157 + TB-500 (Thymosin Beta-4)
The most commonly referenced research combination for systemic healing. These two peptides are thought to have complementary mechanisms: BPC-157 promotes angiogenesis and growth factor signaling, while TB-500 promotes cell migration and actin polymerization. For a detailed comparison, see BPC-157 vs TB-500: Healing Peptide Research Comparison 2026.
For combined protocol considerations, see the BPC-157 + TB-500 Stack Protocol Guide.
BPC-157 + KPV for Gut Research
KPV (Lysine-Proline-Valine), the C-terminal tripeptide of alpha-MSH, has complementary anti-inflammatory and gut mucosal protective properties. Some researchers study this combination for gastrointestinal applications.
BPC-157 in Immune Stack Research
BPC-157 has been examined as part of broader immune-modulating stacks. See the Immune Defense Peptide Stack 2026 for context on multi-peptide immune research protocols.
---
Sourcing and Quality Considerations
Research-grade BPC-157 should meet minimum quality standards for legitimate research use:
- •Certificate of Analysis (COA): HPLC purity ≥98%; mass spectrometry confirmation of molecular weight
- •Sterility testing: Endotoxin testing for injectable-grade material
- •Storage: Lyophilized form stable at -20°C; reconstituted material refrigerated at 4°C
Compare verified supplier listings, pricing, and available documentation at peptides.so/compare/bpc-157.
---
Summary
BPC-157 is one of the most extensively researched synthetic peptides in preclinical literature, with documented activity across gastrointestinal healing, tendon and ligament repair, angiogenesis, and nitric oxide modulation. Its unique gastric-juice-derived stability makes it an interesting candidate for both injectable and oral research applications. The most robust evidence base exists for gut healing and tendon repair models in rodents, with CNS and systemic anti-inflammatory research expanding the literature.
As with all research peptides, BPC-157's preclinical findings remain to be validated in rigorous human clinical trials. Researchers should approach this compound with appropriate scientific skepticism and consult peer-reviewed literature directly when designing research protocols.
---
> For Research Purposes Only. BPC-157 is not approved by the FDA or any regulatory authority for human therapeutic use. This article is intended for educational purposes and for individuals with appropriate research credentials. Not for human use.
---
CNS and Neuroprotection Research
Beyond its well-documented gastrointestinal and musculoskeletal effects, BPC-157 has generated substantial research interest for central nervous system (CNS) applications. A series of studies in rodent models of CNS injury and neurological dysfunction have reported effects that include:
Traumatic Brain Injury Models: In rat TBI models, BPC-157 administration was associated with reduced lesion volume, improved behavioral outcomes on motor and cognitive tests, and preserved blood-brain barrier integrity compared to vehicle controls. The proposed mechanisms involve its angiogenic and NO-modulating properties, which support vascular repair in injured CNS tissue.
Parkinson's Disease Models: Rodent models of dopaminergic neurotoxicity (6-OHDA and MPTP models) have been examined, with some studies demonstrating neuroprotective effects on substantia nigra dopaminergic neurons. BPC-157's interaction with the dopaminergic system has been specifically studied, with researchers proposing that its influence on the NO system modulates dopamine receptor sensitivity.
Depression and Behavior: A subset of BPC-157 research has examined behavioral effects in rodent models. Studies using forced swim tests and elevated plus maze protocols have reported effects consistent with anti-depressant and anxiolytic-like activity, though the biological basis for these behavioral observations remains under investigation.
Spinal Cord Injury: Limited but intriguing preclinical data exists on BPC-157 in spinal cord injury models, with some studies reporting improved functional recovery scores compared to vehicle controls.
Important limitation: CNS research on BPC-157 is less replicated than its gut and tendon data, and the mechanisms proposed in this domain rely heavily on the same angiogenesis/NO/growth factor framework established elsewhere. Independent verification in non-Sikirić group laboratories is more limited in CNS contexts.
---
Oral vs. Injectable BPC-157: Administration Route Research
One of the most scientifically interesting aspects of BPC-157 is its demonstrated activity via oral administration — unusual for a peptide of its size, as most peptides are degraded in the GI tract before absorption.
The basis for this oral activity is BPC-157's remarkable stability in gastric acid conditions — a property that makes biological sense given that it was originally characterized from gastric juice protein. Studies have demonstrated that BPC-157 retains structural integrity across the acid pH of the stomach, allowing at least partial absorption through the intestinal mucosa.
Oral vs. Injectable Evidence Comparison:
| Parameter | Injectable | Oral |
|---|---|---|
| Route | SC, IM, IP | Oral gavage |
| Literature depth | Extensive | Moderate |
| Systemic effects | Well-documented | Demonstrated in some models |
| Gut-specific effects | Strong | Strong (may be superior for local effects) |
| Bioavailability | High (assumed) | Uncertain (species-dependent) |
Notably, for gut-targeted research applications (IBD models, mucosal protection), some researchers have observed comparable or even superior effects via oral route — which makes mechanistic sense, as oral administration maintains the peptide in contact with the intestinal mucosa that is the primary target.
For a detailed comparison of these administration routes, see BPC-157 Oral vs Injectable: Administration Route Research Guide 2026.
---
BPC-157 in Systemic Disease Models
Beyond its localized tissue applications, BPC-157 has been studied in systemic disease models where organ protection across multiple systems is relevant:
Liver Injury Models: In models of hepatotoxin-induced liver injury (e.g., CCl4 toxicity), BPC-157 has shown hepatoprotective effects. Researchers attribute this to its NO system effects and preservation of hepatic vasculature.
Kidney Protection: Some studies in renal ischemia-reperfusion models report reduced markers of kidney injury following BPC-157 administration, again linked to vascular protective mechanisms.
Heart and Cardioprotection: A subset of the BPC-157 literature examines cardiac injury models, with reported effects on reducing infarct size and preserving cardiac function after ischemia-reperfusion injury in rodents.
Peripheral Vascular Disease Models: BPC-157's angiogenic properties have been examined in limb ischemia models, where VEGF-mediated neovascularization could theoretically restore perfusion to ischemic peripheral tissue.
---
Safety Considerations in Preclinical Research
No peer-reviewed publications have documented toxicity associated with BPC-157 in animal research at doses studied in the literature. The peptide's gastric origin and relatively small size (15 amino acids) have led researchers to suggest it may have a favorable safety profile at studied doses. However:
- •No long-term rodent toxicology studies have been published (the standard preclinical safety battery)
- •No human safety data exists from controlled trials — individual case reports or anecdotal accounts are not scientific evidence
- •Cancer concern: Some researchers have raised theoretical concerns about pro-angiogenic peptides in the context of established tumors (VEGF upregulation could theoretically support tumor vascularization), though no BPC-157 carcinogenicity data exists in the literature
- •Regulatory status: BPC-157 is explicitly not approved for any human indication in any jurisdiction
---
Research Protocol Design Considerations
Researchers designing studies with BPC-157 should be aware of the following methodological context from published literature:
Dose ranges used in animal studies: Published rodent studies typically used doses in the range of 1–10 mcg/kg to 10–100 mcg/kg body weight, with some studies using mg/kg doses. These wide variations reflect different administration routes and experimental endpoints.
Frequency: Most studies administered BPC-157 once daily (for injectable routes) or in drinking water (for oral). The once-daily SC/IP protocol is the most common.
Duration: Short-term studies (3–14 days) dominate the acute healing literature; some IBD and behavioral studies extend to 3–8 weeks.
Animal models: Sprague-Dawley and Wistar rats dominate the BPC-157 literature. Fewer mouse studies exist, limiting direct comparison to commonly used transgenic mouse models in inflammation research.
For detailed protocol considerations, see the BPC-157 Dosage & Research Protocol Guide 2026.
---
Research Landscape and Critical Assessment
It is important to note a significant publication concentration issue in the BPC-157 literature: the majority of animal studies — particularly those studying CNS effects and complex behavioral outcomes — originate from a single research group led by Dr. Predrag Sikirić at the University of Zagreb. While this group's contributions have been substantial and the gastrointestinal findings have been independently replicated in several settings, the lack of independent replication across the broader literature is a legitimate scientific concern.
What has reasonable independent support:
- •Gut mucosal protection and anti-ulcer activity (multiple independent groups)
- •Angiogenesis and VEGF upregulation (replicated in several tendon/healing models)
- •NO system interaction (replicated in pharmacological studies)
What needs more independent replication:
- •CNS and behavioral effects (concentrated in single group)
- •Systemic disease model effects (limited independent data)
- •Oral bioavailability parameters (limited independent characterization)
Researchers should weight this context appropriately when designing studies and interpreting results.